Dermata reports Q2 2023 cash $8.4M; FDA agrees Phase 3 design for DMT310 acne

Dermata Therapeutics, Inc.

Cash $8.4M at June 30, 2023 vs $6.2M at Dec 31, 2022; net $5.7M from two 2023 financings.
FDA agreed Phase 3 program acceptable for NDA; co-primary endpoints acceptable.
Phase 3 STAR-1 study for DMT310 acne expected to start enrollment in 2H 2023.
R&D expenses $0.8M Q2 2023 vs $1.6M Q2 2022; G&A $0.9M vs $1.1M.
Cash resources expected to fund operations into Q2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dermata Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $8.4 million in cash and cash equivalents.

Period: the second quarter ended June 30, 2023
Revenue: $8.4 million in cash and cash equivalents
Result: reported results

Exact text from the filing

to pursue partnership discussions for its DMT410 program for the topical delivery of botulinum toxin. Second Quarter 2023 Financial Results As of June 30, 2023, Dermata had $8.4 million in cash and cash equivalents, compared to $6.2 million as of December 31, 2022. The increase in cash and cash equivalents resulted from $5.7 million net proceeds from the

View on SEC.gov

Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-010489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.